Company / SG&A Expense
Bausch Health Companies Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$3.4B
FY2025
5-year range
$2.4B / $3.4B
FY2021-FY2025
Trend
+4.3%
vs FY2024
Sector context
#10 of 213
Health Care
What the data says
Among 213 Health Care companies, Bausch Health Companies Inc. is in the bottom 5% for sg&a expense. SG&A Expense has increased for 3 consecutive years, from $2.4B in FY2022 to $3.4B in FY2025.
Based on SEC 10-K filings.
$3.4B in FY2025 with a 5-year CAGR of +6.8%. Top quartile in the Health Care sector.
Increased from $2.6B to $3.4B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +13.2%
- 5-Year CAGR
- +6.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 213This company $3.4B Sector average $722.3M
▼
+376.0% above sector average
Key checks
Key Insights
- Bausch Health Companies Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +6.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 4.3% year-over-year.
- Ranks #10 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.4B | +4.3% |
| FY2024 | $3.3B | +25.6% |
| FY2023 | $2.6B | +10.9% |
| FY2022 | $2.4B | -9.8% |
| FY2021 | $2.6B | +6.1% |
| FY2020 | $2.5B | -4.2% |
| FY2019 | $2.6B | -8.1% |
| FY2018 | $2.8B | +8.8% |
| FY2017 | $2.6B | -8.1% |
| FY2016 | $2.8B | +4.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026